SIGBAN 150 SR Tablet is a specialized sustained-release formulation of Bupropion Hydrochloride, an atypical antidepressant that functions by modulating neurotransmitter activity in the brain. This medication is indicated for the treatment of major depressive disorder (MDD) and is also widely prescribed as a smoking cessation aid under controlled therapeutic guidance. It acts by inhibiting the reuptake of norepinephrine and dopamine—two crucial neurotransmitters associated with mood regulation and addiction mechanisms.

Unlike traditional antidepressants that often work on serotonin levels, Bupropion has a unique mechanism of action that helps uplift mood, increase motivation, and restore a sense of emotional balance without inducing drowsiness. This characteristic makes SIGBAN 150 SR an ideal option for individuals who suffer from low energy, concentration difficulties, or anhedonia related to depression but want to avoid the sedative effects that come with other medications.

The sustained-release (SR) design of SIGBAN 150 ensures a gradual release of the active ingredient over several hours, maintaining stable blood levels throughout the day and minimizing the risk of sudden peaks that could cause side effects. This steady delivery mechanism allows for better control over symptoms and improves patient adherence by enabling a convenient twice-daily dosing schedule.

In patients battling major depression, SIGBAN 150 SR helps alleviate core symptoms such as persistent sadness, loss of interest in daily activities, changes in appetite or sleep, fatigue, feelings of guilt or worthlessness, and suicidal thoughts. The therapeutic effect typically begins to manifest within two to four weeks of continuous use, although individual responses may vary. Physicians often monitor patients closely during the initial treatment phase to evaluate efficacy and adjust dosing if needed.

In smoking cessation, SIGBAN 150 SR plays a significant role by curbing nicotine cravings and reducing withdrawal symptoms such as irritability, anxiety, restlessness, and difficulty concentrating. The medication helps rebalance the brain’s reward system, making it easier for individuals to break free from nicotine dependence. It is commonly used as part of a comprehensive cessation program that may include behavioral therapy and lifestyle counseling. Treatment usually starts one to two weeks before the chosen quit date, continuing for several weeks or months based on the physician’s recommendation.

Although effective, SIGBAN 150 SR Tablet should only be used under the supervision of a qualified healthcare provider. Patients with a history of seizures, eating disorders such as bulimia or anorexia nervosa, or alcohol or benzodiazepine withdrawal are generally advised against using this medication due to an increased risk of seizures. Other precautions include monitoring for behavioral changes, mood swings, or suicidal ideation, especially in the early stages of treatment or when the dose is altered.

Side effects associated with SIGBAN 150 SR are usually mild and transient, including insomnia, dry mouth, dizziness, increased sweating, agitation, and occasional headaches. Taking the tablet early in the day and avoiding alcohol can reduce the likelihood of these adverse effects. Serious side effects are rare but require immediate medical attention if they occur.

SIGBAN 150 SR Tablet is manufactured under strict GMP-certified quality standards, ensuring every batch is consistent in strength, purity, and safety. It comes in robust packaging to protect the integrity of the sustained-release mechanism and ensure proper therapeutic delivery until the expiration date.